Evidence map›Paper›PMID 41001453›Full record

ArticlemedRxiv : the preprint server for health sciences2025

A phase 1 randomized, placebo-controlled trial of a combination typhoid and non-typhoidal

Wilbur H Chen, Robin S Barnes, Michael J Sikorski, Reva Datar, Roohali Sukhavasi, Yuanyuan Liang, Rekha R Rapaka, Marcela F Pasetti, Marcelo B Sztein, Rezwanul Wahid and 13 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Wilbur H ChenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.ORCID 0000-0001-7741-5536
Robin S BarnesCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Michael J SikorskiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Reva DatarCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Roohali SukhavasiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Yuanyuan LiangDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Rekha R RapakaCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Marcela F PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Marcelo B SzteinCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Rezwanul WahidCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Sharon M TennantCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Raphael SimonCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Scott M BalibanCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
James E GalenCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Andrew LeesCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.
Biana BernshteinRagon Institute, Harvard Medical School, Cambridge, MA, U.S.A.
Galit AlterRagon Institute, Harvard Medical School, Cambridge, MA, U.S.A.
Raches EllaBharat Biotech International Ltd, Hyderabad, Telangana, India.
Krishna MohanBharat Biotech International Ltd, Hyderabad, Telangana, India.
M Gangadhara NaiduBharat Biotech International Ltd, Hyderabad, Telangana, India.
D Yogeswar RaoBharat Biotech International Ltd, Hyderabad, Telangana, India.
Krishna M EllaBharat Biotech International Ltd, Hyderabad, Telangana, India.
Myron M LevineCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, U.S.A.

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FRASER, CLAIRE M. · 2009 to 2018
$27.8M
IMMUNE MECHANISMS OF PROTECTION IN S TYPHI VACCINESR01AI036525 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1994 to 2026
$12.2M
Systems Biology and Biostatistics CoreU19AI181108 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Rosangela Mezghanni · 2024 to 2026
$8.0M
NCI NIH HHS P30 CA134274NIAID NIH HHS R01 AI036525NIAID NIH HHS U19 AI082655NIAID NIH HHS U19 AI181108Wellcome Trust
6 · The paper itself

Abstract

In sub-Saharan Africa, non-typhoidal

Identifiers

PMID41001453
PMCPMC12458498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.